Biblio
“HPV‐related cervical diseases: Alteration of vaginal microbiotas and promising potential for diagnosis”, Journal of Medical Virology, vol. 95, no. 1, 2023.
, “Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial”, NEJM Evidence, vol. 2, no. 5, 2023.
, “Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.”, J Clin Oncol, vol. 41, no. 4, pp. 893-902, 2023.
, “Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup”, The Lancet Oncology, vol. 23, no. 8, pp. e374 - e384, 2022.
, “Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.”, Lancet, vol. 399, no. 10324, pp. 541-553, 2022.
, “The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries.”, Int J Gynecol Cancer, 2021.
, “Cervix Cancer in Sub-Saharan Africa: An Assessment of Cervical Cancer Management.”, JCO Glob Oncol, vol. 7, pp. 173-182, 2021.
, “ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.”, Int J Gynecol Cancer, vol. 31, no. 10, pp. 1317-1325, 2021.
, “Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.”, J Natl Cancer Inst, vol. 113, no. 7, pp. 917-923, 2021.
, “Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer”, JAMA Oncology, vol. 7, no. 6, p. 853, 2021.
, “Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.”, Gynecol Oncol, 2021.
, “Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial”, Journal of Gynecologic Oncology, vol. 32, no. 5, 2021.
, “Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial”, The Lancet Oncology, vol. 22, no. 5, pp. 620 - 631, 2021.
, “A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.”, Gynecol Oncol, vol. 163, no. 1, pp. 72-78, 2021.
, “Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy”, European Journal of Cancer, vol. 154, pp. 190 - 200, 2021.
, “Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer”, New England Journal of Medicine, vol. 385, no. 23, pp. 2123 - 2131, 2021.
, “Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.”, JAMA Netw Open, vol. 3, no. 1, p. e1918939, 2020.
, “Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).”, Int J Gynecol Cancer, vol. 30, no. 12, pp. 1997-2001, 2020.
, “Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.”, Lancet Oncol, vol. 21, no. 5, pp. 699-709, 2020.
, “Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference.”, Int J Gynecol Cancer, 2020.
, “Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy”, European Journal of Cancer, vol. 139, pp. 59 - 67, 2020.
, “Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors”, JAMA Oncology, vol. 6, no. 12, p. 1923, 2020.
, “Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).”, Int J Gynecol Cancer, vol. 30, no. 4, pp. 509-514, 2020.
, “Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study”, Journal of Gynecologic Oncology, vol. 31, 2020.
, “Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.”, Gynecol Oncol, vol. 152, no. 2, pp. 235-242, 2019.
,